These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 15829410

  • 1. Immunomodulatory activity of analog of muramyl dipeptide and their use as adjunct to chemotherapy of Leishmania donovani in hamster.
    Puri A, Sahai R, Haq W, Zaidi A, Guru PY, Tripathi LM, Srivastava VM.
    Int Immunopharmacol; 2005 Jun; 5(6):937-46. PubMed ID: 15829410
    [Abstract] [Full Text] [Related]

  • 2. Protective effect of neoglycoprotein-conjugated muramyl dipeptide against Leishmania donovani infection: the role of cytokines.
    Sarkar K, Das PK.
    J Immunol; 1997 Jun 01; 158(11):5357-65. PubMed ID: 9164956
    [Abstract] [Full Text] [Related]

  • 3. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.
    Mazumdar T, Anam K, Ali N.
    Vaccine; 2004 Mar 12; 22(9-10):1162-71. PubMed ID: 15003644
    [Abstract] [Full Text] [Related]

  • 4. Leishmania donovani: CD2 biased immune response skews the SAG mediated therapy for a predominant Th1 response in experimental infection.
    Bimal S, Sinha S, Singh SK, Narayan S, Kumar V, Verma N, Ranjan A, Sinha PK, Das VN, Pandey K, Kar SK, Das P.
    Exp Parasitol; 2012 Jul 12; 131(3):274-82. PubMed ID: 22580024
    [Abstract] [Full Text] [Related]

  • 5. Comparative study of immunomodulatory properties of muramyl peptides on immune system cells of young and old mice.
    Dozmorov IM, Kuzin II, Lutsan NI, Lutsenko GV, Prokhorova AL, Sapozhnikov AM, Andronova TM, Ivanov VT.
    Immunopharmacol Immunotoxicol; 1994 May 12; 16(2):149-63. PubMed ID: 8077604
    [Abstract] [Full Text] [Related]

  • 6. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
    Lemesre JL, Holzmuller P, Gonçalves RB, Bourdoiseau G, Hugnet C, Cavaleyra M, Papierok G.
    Vaccine; 2007 May 22; 25(21):4223-34. PubMed ID: 17395339
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Prophylactic efficacy of high-molecular-weight antigenic fractions of a recent clinical isolate of Leishmania donovani against visceral leishmaniasis.
    Tripathi P, Gupta SK, Sinha S, Sundar S, Dube A, Naik S.
    Scand J Immunol; 2008 Nov 22; 68(5):492-501. PubMed ID: 18803606
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Muramyl dipeptide and its synthetic analog as possible inducers of interleukin-2 production].
    Malaĭtsev VV, Bogdanov IM, Sukhikh GT, Andronova TM.
    Biull Eksp Biol Med; 1985 Aug 22; 100(8):221-3. PubMed ID: 3875372
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Changes in purine metabolism in the macrophages of mice exposed to a new synthetic analog of muramyl dipeptide].
    Umanskiĭ VIu, Tarakhovskiĭ AM, Andronova TM.
    Biull Eksp Biol Med; 1985 Jun 22; 99(6):685-7. PubMed ID: 2990603
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.